All news

STRO Reiterated by Wedbush -- Price Target Maintained at $60

Alpha Vantage · GuruFocus · · AI-summarised by FinFlash

Wedbush has reiterated an Outperform rating for Sutro Biopharma (STRO), maintaining a price target of $60.00, despite the stock currently trading significantly above its GF Value™ of $4.89. The company's GF Score™ of 42/100 indicates weaknesses in profitability and valuation, leading to a cautious outlook for investors. Gurus are also showing caution, with 2 out of 3 trimming their positions.

Read original source

STRO company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.